WL Gore & Associates (Gore) has reported the first clinical uses of the GORE C3 delivery system to deploy the GORE Excluder AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).
The US Food and Drug Administration approved GORE C3 delivery system provides the clinician with the ability to reposition the Gore Excluder device prior to final release from the delivery catheter.
The added deployment control provides physicians increased confidence in treating challenging anatomies, as well as cannulation options with the ability to bring the contralateral gate to the contralateral guidewire.
The GORE Excluder device remains virtually unchanged, maintaining the same low delivery profile and flexibility on catheter that facilitates access and passage through narrow and tortuous anatomies.
Gore said the ability to reposition the device may minimize complications that could occur if the graft needs to be repositioned after the initial deployment.
University of Pittsburgh Medical Center (UPMC) Vascular Surgery division chief Makaroun said a 70-year-old woman with a large aneurysm and diseased aortic neck successfully received the first Gore Excluder AAA Endoprosthesis with the GORE C3 Delivery System at UPMC.
"The recapture mechanism worked nicely to allow repositioning of the GORE Excluder Device, a feature that will increase our confidence in treating challenging aortic neck anatomies and the deployment mechanism remains quite simple and easy to use," Makaroun said.